These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 17404856)

  • 1. Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH).
    Hussein O; Grosovski M; Schlesinger S; Szvalb S; Assy N
    Dig Dis Sci; 2007 Oct; 52(10):2512-9. PubMed ID: 17404856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis.
    Sabuncu T; Nazligul Y; Karaoglanoglu M; Ucar E; Kilic FB
    Rom J Gastroenterol; 2003 Sep; 12(3):189-92. PubMed ID: 14502318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
    Witek RP; Stone WC; Karaca FG; Syn WK; Pereira TA; Agboola KM; Omenetti A; Jung Y; Teaberry V; Choi SS; Guy CD; Pollard J; Charlton P; Diehl AM
    Hepatology; 2009 Nov; 50(5):1421-30. PubMed ID: 19676126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis.
    Assy N; Hussein O; Abassi Z
    Gut; 2007 Mar; 56(3):443-4. PubMed ID: 17339254
    [No Abstract]   [Full Text] [Related]  

  • 5. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial.
    Harrison SA; Fecht W; Brunt EM; Neuschwander-Tetri BA
    Hepatology; 2009 Jan; 49(1):80-6. PubMed ID: 19053049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis.
    Harrison SA; Torgerson S; Hayashi P; Ward J; Schenker S
    Am J Gastroenterol; 2003 Nov; 98(11):2485-90. PubMed ID: 14638353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.
    Liew PL; Lee WJ; Lee YC; Wang HH; Wang W; Lin YC
    Obes Surg; 2006 Dec; 16(12):1584-93. PubMed ID: 17217634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease.
    Zelber-Sagi S; Kessler A; Brazowsky E; Webb M; Lurie Y; Santo M; Leshno M; Blendis L; Halpern Z; Oren R
    Clin Gastroenterol Hepatol; 2006 May; 4(5):639-44. PubMed ID: 16630771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.
    Nelson A; Torres DM; Morgan AE; Fincke C; Harrison SA
    J Clin Gastroenterol; 2009; 43(10):990-4. PubMed ID: 19448566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.
    Angulo P; Keach JC; Batts KP; Lindor KD
    Hepatology; 1999 Dec; 30(6):1356-62. PubMed ID: 10573511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients.
    Harrison SA; Fincke C; Helinski D; Torgerson S; Hayashi P
    Aliment Pharmacol Ther; 2004 Sep; 20(6):623-8. PubMed ID: 15352910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orlistat in the treatment of NASH: a case series.
    Harrison SA; Ramrakhiani S; Brunt EM; Anbari MA; Cortese C; Bacon BR
    Am J Gastroenterol; 2003 Apr; 98(4):926-30. PubMed ID: 12738478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic fatty liver disease in severely obese subjects.
    Gholam PM; Flancbaum L; Machan JT; Charney DA; Kotler DP
    Am J Gastroenterol; 2007 Feb; 102(2):399-408. PubMed ID: 17311652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years.
    Powell EE; Cooksley WG; Hanson R; Searle J; Halliday JW; Powell LW
    Hepatology; 1990 Jan; 11(1):74-80. PubMed ID: 2295475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.
    Micić D; Ivković-Lazar T; Dragojević R; Jorga J; Stokić E; Hajduković Z
    Med Pregl; 1999; 52(9-10):323-33. PubMed ID: 10624380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease.
    Larter CZ; Yeh MM; Haigh WG; Van Rooyen DM; Brooling J; Heydet D; Nolan CJ; Teoh NC; Farrell GC
    Obesity (Silver Spring); 2013 Jun; 21(6):1189-99. PubMed ID: 23666886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous administration of multipotent stromal cells prevents the onset of non-alcoholic steatohepatitis in obese mice with metabolic syndrome.
    Ezquer M; Ezquer F; Ricca M; Allers C; Conget P
    J Hepatol; 2011 Nov; 55(5):1112-20. PubMed ID: 21356258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The serum endothelin-1 level in steatosis and NASH, and its relation with severity of liver fibrosis.
    Degertekin B; Ozenirler S; Elbeg S; Akyol G
    Dig Dis Sci; 2007 Oct; 52(10):2622-8. PubMed ID: 17429733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression.
    Ekstedt M; Franzén LE; Mathiesen UL; Kechagias S
    Scand J Gastroenterol; 2012 Jan; 47(1):108-15. PubMed ID: 22126450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.